Loading...
XTAE
REKA
Market cap41mUSD
Dec 04, Last price  
1,172.00ILS
1D
0.00%
1Q
-0.17%
Jan 2017
-43.84%
Name

Rekah Pharmaceutical Industry Ltd

Chart & Performance

D1W1MN
XTAE:REKA chart
P/E
21.56
P/S
0.42
EPS
0.54
Div Yield, %
Shrs. gr., 5y
0.97%
Rev. gr., 5y
10.36%
Revenues
322m
+0.02%
269,998,000270,032,000216,372,000262,429,000218,385,000208,184,000207,829,000196,499,000265,473,000263,950,000292,394,000321,663,000321,712,000
Net income
6m
P
7,403,0008,320,000-501,000-4,414,000-11,000,000-22,480,0007,027,0002,755,00010,797,0006,624,000-2,043,000-6,910,0006,206,000
CFO
27m
-6.38%
14,182,00011,706,0001,330,0005,806,00022,825,00023,797,00017,284,00033,913,00011,283,00021,169,00039,002,00028,350,00026,541,000
Dividend
Apr 06, 202286.776 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.
IPO date
Dec 14, 1995
Employees
399
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT